You are here

Article Text

Article menu
Download PDFPDF
Review
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors
  1. P J Mease
  1. Correspondence to:
    Professor P J Mease, Seattle Rheumatology Associates, 1101 Madison St, Seattle, WA 98104, USA;
    pmease{at}u.washington.edu

Abstract

High levels of proinflammatory cytokines, including tumour necrosis factor (TNF), have been detected in psoriatic skin lesions and joints of patients with the inflammatory disease. Early results of treatment of psoriatic arthritis and psoriasis with TNF neutralising agents are encouraging, but whether these agents will be able to improve long term outcomes, such as disability, is not yet known.

  • psoriatic arthritis
  • tumour necrosis factor
  • DIP, distal interphalangeal
  • DMARDs, disease modifying antirheumatic drugs
  • IM, intramuscular
  • MTX, methotrexate
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • PASI, Psoriasis Area and Severity Index
  • PsA, psoriatic arthritis
  • RA, rheumatoid arthritis
  • SSZ, sulfasalazine
  • TNF, tumour necrosis factor

https://doi.org/10.1136/ard.61.4.298

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes